PHAXIAM provides Business and Financial Update for the First Quarter of 2024

PHAXIAM provides Business and Financial Update
for the First Quarter of 2024

Webinar (in French) today, May 15, 2024, at 6.00 pm CEST

• Accelerated clinical efforts to roll-out PHAXIAM’s strategy in order to create a global phage-therapy leader in high-value indications
• Cash and cash equivalents of €5.8 million, as of March 31, 2024

Lyon (France) and Cambridge (MA, US), May 15, 2024, at 5.45 pm CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today provides a business and financial update for the first quarter of 2024.

Thibaut du Fayet, Chief Executive Officer of PHAXIAM Therapeutics, stated: “Almost a year after the creation of PHAXIAM, the company is well on track to become a leading player in phage therapies targeting the most severe bacterial infections. Indeed, we have successfully refocused our clinical programs to indications of high medical needs to provide a therapeutic alternative mainly to patients with severe and resistant Staphylococcus aureus infections, often associated with high mortality and strong impact on healthcare budgets.

This is particularly the case for Prosthetic Joint Infections, where PHAXIAM plans to strengthen its leading competitive position through an upcoming first global Phase 2 study, but also for Endocarditis Infections, with the beginning, a couple of weeks ago, of a unique Phase 1 study in this indication with phage therapy.

Beyond these two strategic clinical studies, our technological platform and know-how enable us to evaluate our phages in additional indications, such as Diabetic Food Ulcer caused by S. aureus, and potentially later, Urinary Tract Severe Infections caused by E. coli, reinforcing our ambition to develop a unique portfolio of innovative therapies for patients who failed traditional antimicrobial treatments.”

BUSINESS HIGHLIGHTS

a)  Important progress for the Staphylococcus aureus (S. aureus) program

• Prosthetic Joint Infections (PJI)
  
  
  • PHAXIAM is accelerating its PJI clinical development efforts through active preparations of a global Phase 2 proof-of-concept (POC) study.
  • The Phase 2 POC study is intended to be a multicentric, randomized, double-blind trial and is expected to include 100 patients in Europe and the US.
  • PHAXIAM confirms its objective to file a Clinical Trial Application (CTA) with the EMA and the FDA in 3Q 2024 in view of starting patient enrollment in early 2025.
  • The Company intends to capitalize on promising activity signals from real-life compassionate treatments and valuable insights from the PhagoDAIR pilot study, the data of which should be available by the end of 2024.